Skip to main content

IL-17

      My favorite three presentations from day 4 at ACR 2021 included the following: Breakthrough Infections in Rheumatic Disease Patients Late-Breaking Abstract L16 - Dr. Jazvinder Singh presented the…
      RT @swethaann23: ⭐️Prevalent drug utilization was not related to enthesitis activity
      ⭐️Prevalent use of cDMARDs
      2 years 7 months ago
      ⭐️Prevalent drug utilization was not related to enthesitis activity ⭐️Prevalent use of cDMARDs 🔼physician GAS compared to TNFi/IL-17i ⭐️No correlation in disease activity scores amongst the use of different prevalent PsA drug Rx Abst# 1782 #ACR21 @RheumNow @doctorRBC https://t.co/uzmTP1hZ2P
      RT @Janetbirdope: #Guselkimab Better than #ustekinumab for skin& MSK. #Ixekizumab beat ustekinumab for skin. #usteki
      2 years 7 months ago
      #Guselkimab Better than #ustekinumab for skin& MSK. #Ixekizumab beat ustekinumab for skin. #ustekinumab loses throne in #psoriasis and #psoriatic arthritis except maybe if concomitant inflammatory bowel disease post TNFi? Rapidly evolving PsA Rx. Abst#1773 #ACR21 @RheumNow https://t.co/Dkf2DFFsSK
      RT @Janetbirdope: IL17 IS Impt in giant cell arthritis. Who would’ve thought that #secukinumab would treat #GCA? More
      2 years 7 months ago
      IL17 IS Impt in giant cell arthritis. Who would’ve thought that #secukinumab would treat #GCA? More options for pts. Only 52 pts but maybe another Rx for GCA? #ACR21 abst#L19 https://t.co/dwbPmGswQ9
      RT @KDAO2011: IL-17i for GCA? TitAIN study met all endpoints!
      phase II: 52 pt DBRPCT 1:1 for 52 weeks secukinumab vs PC
      2 years 7 months ago
      IL-17i for GCA? TitAIN study met all endpoints! phase II: 52 pt DBRPCT 1:1 for 52 weeks secukinumab vs PCB 👉effective sustained remission 👉longer time to GCA flare 👉lower dose of steroids by week 52 👉no increase in AEs #ACR21 @rheumnow Abst#L19 https://t.co/Xi3Iz6Em0R
      RT @uptoTate: Prevalent drug utilization unrelated to enthesitis in PsA. Pts on cDMARDs had higher physician globals vs
      2 years 7 months ago
      Prevalent drug utilization unrelated to enthesitis in PsA. Pts on cDMARDs had higher physician globals vs those treated w/TNFi & IL-17i. In aggregate, no pattern of dz activity scores correlation w/drugs. Abs 1782 #ACR21 #RheumNow @RheumNow @doctorRBC https://t.co/x57BkBjpjo https://t.co/QmdXqOxLki
      RT @DrPetryna: Abst1810 #acr21 @RheumNow survey of pt preferred meds for PsA points out ⬆️ interest in IL17 & PD
      2 years 7 months ago
      Abst1810 #acr21 @RheumNow survey of pt preferred meds for PsA points out ⬆️ interest in IL17 & PDE4 since 2018 guideline update: anti-IL17 compared to 2018 or earlier (30% vs 3.5% p< 0.001);anti-PDE4 (40% vs 11.5% p< 0.012). Meds SEs& prevention of joint damage important for pts
      RT @doctorRBC: After 2018 ACR Guidelines, significant increase in IL-17i and PDE4i use in PsA pts
      ⭐️TNFi most common
      2 years 7 months ago
      After 2018 ACR Guidelines, significant increase in IL-17i and PDE4i use in PsA pts ⭐️TNFi most common tx ⭐️28% pts not on any tx⭐️ #ACR21 @RheumNow Abs#1810 https://t.co/7Rmirfm3nK https://t.co/0Ui9pq5uyo